Quick CV Dropoff
Quick CV Drop Off Form - Description
Introducing
Automata: Synthetic Biology.
Automata is on a mission to revolutionise synthetic biology, with its lab automation platform.
The technology shortens turnaround times by scaling capacities and allows scientists to spend more time on their analyses - which also leads to cost reductions.
Now is such an exciting time to join the London-based start-up. Having secured $50m in series B funding, the business is primed for growth in life sciences. This is strengthened by key partnerships with household names like AusDiagnostics, Flow Robotics and Opentrons.
Automata's systems have also been successfully utilised by NHS pathology labs to help them meet backlogs and upscale capacity, in one of these labs they are running 40 fully automated stations 24/7.
Having expanded three-fold last year, they’re ready to replicate this growth and want synthetic biology talent to lead them on this journey.
About the
Synthetic Biology Lab Pod
Learn more about Automata's expertise in synthetic biology from its specialist team. Click to watch the video.
About the
NHS Partnership.
In 2021, in the height of the COVID-19 pandemic, Automata worked with the University Hospital Southampton NHS Foundation Trust to automate Reverse Transcript Loop-mediated isothermal amplification (RT-LAMP) testing.
Working alongside engineers from the programme, Automata designed and implemented automated liquid handling systems within six months. The results have been transformative, with unprecedented volumes of tests carried out per day.
The success of the partnership has led Automata and UHS to explore further opportunities together. For example, automating other manual elements of the existing RT-LAMP testing process, as well as streamlining other complementary diagnostic processes.
About
$50 Million in Series B Financing.
The investment round was led by Octopus Ventures with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital - as well as strategic investors such as In-Q-Tel, among others.
This investment will enable significant development, in the UK and beyond, of Automata Labs for scientists working across diagnostics.
The Series B investment is on the back of rapid growth for Automata, whose focus on the life sciences has seen nearly a million tests conducted by scientists and clinicians in recent months.
Introducing
CM Life Science.
We are a global provider of talent solutions for the life science industry. We are really excited to partner with Automata for its expansion. If you have any questions about a career with the business, please feel free to contact us.